World News

The sale came about following an unsolicited offer from BGH Capital, which focuses on investments in Australia and New Zealand.

The deal collapsed after STAAR failed to secure sufficient shareholder approval during a special stockholders meeting held on January 6.

Amgen’s latest acquisition is centered on Dark Blue’s lead candidate, DBT 3757, which specifically treats acute myeloid leukemia that affects bone marrow and blood cells.

Sanofi will leverage Earendil’s artificial intelligence (AI)-powered drug discovery platform to support the design and development of multiple new therapeutic assets.

The collaboration aimed to support the distribution of Valneva’s single-dose vaccine, Ixchiq, in low- and middle-income countries (LMICs) across Asia.

Through this agreement, Sanofi will gain full ownership of Heplisav-B, a two-dose hepatitis B vaccine that received US approval in 2017 and European authorization in 2021.

Through this acquisition, J&J gains access to HLD-0915, a clinical-stage, once-daily oral therapy intended for the treatment of prostate cancer.

With this latest authorisation, individuals now have access to a long-acting option for prevention rather than daily pill-based regimens.

This deal gives Samsung Biologics its first manufacturing site in the US and reinforces its long-term commitment to serving the North American biopharmaceutical market.

The therapy is indicated for patients aged 12 years and older with severe asthma characterized by an eosinophilic phenotype.